Mastorino, Luca published the artcileRisankizumab shows high efficacy and maintenance in improvement of response until week 52, Safety of Dimethyl fumarate, the publication is Dermatologic Therapy (2022), 35(5), e15378, database is CAplus and MEDLINE.
Risankizumab has been recently approved for moderate-to-severe plaque psoriasis; however, real-life studies are scarce. Anal. of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biol. experience. Our objectives were to evaluate the effectiveness and safety of Risankizumab and to investigate on possible predictor factors response. We retrospectively analyzed 166 patients from two centers in Italy who undergone Risankizumab for psoriasis. The proportion of patients achieving a 100%, 90%, 75% of improvement in Psoriasis Area Severity Index (PASI) and PASI <3 were collected at weeks 16, 28, 40, and 52. Study population was analyzed in subgroups to investigate possible predictors of response to Risankizumab since week 40. At the time of anal. 165, 103, 30, and 11 patients had completed 16, 28, 40, and 52 wk of treatment, resp. The mean PASI score decreased from 12.5 ± 5.1 at baseline to 1.9 ± 2.4 at week 16. Similar reductions were observed when considering PASI <3, PASI 75, PASI 90, and PASI 100. Previous biologics failure, different smoking habits, obesity, and joint involvement resulted in a lower response to risankizumab. In particular, significant differences in mean PASI at any time-points was observed between psoriatic arthritis (PSA) and non-PSA patients: 2.7 vs. 1.7 (p = 0.036), 1.9 vs. 0.4 (p = 0.006), and 4.1 vs. 0.5 (p = 0.016) at 16, 28, and 40 wk, resp. No difference in response to risankizumab occurred in the case of involvement of difficult-to-treat areas. In this population, Risankizumab was effective and safe. Smoking habits, joint involvement, obese status, and previous biol. experience may neg. affect treatment response, while difficult body sites involvement have minor impact.
Dermatologic Therapy published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, Safety of Dimethyl fumarate.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics